India, Oct. 1 -- Thursday, Sun Pharmaceutical Industries Limited (SUNPHARMA) reported two-year safety and efficacy data for LEQSELVI (deuruxolitinib) in adults with severe alopecia areata at the 2026 European Academy of Dermatology and Venereology (EADV) Congress.
The data from a European open-label extension study showed that the safety profile of LEQSELVI remained generally consistent with previous clinical experience through two years of treatment. Most treatment-emergent adverse events were mild or moderate, while treatment discontinuations due to adverse events were uncommon.
Severe Alopecia Areata & LEQSELVI
Alopecia areata is a chronic autoimmune disease in which the immune system attacks hair follicles, resulting in hair loss on ...